Full-Time

Head of Clinical Operations

Confirmed live in the last 24 hours

Tessera Therapeutics

Tessera Therapeutics

201-500 employees

Develops gene writing technology for genetic medicine

Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform
Requirements
  • MS, MBA, MPH or PhD with 15+ years of industry experience, 10+ years of clinical operations line management experience.
  • Excellent understanding and demonstrated application of FDA guidelines, Good Clinical Practice (GCP), ICH and applicable Standard Operating Procedures.
Responsibilities
  • Leading all operational aspects of clinical studies and patient registries to achieve corporate goals for timelines, budget and quality.
  • Selecting and overseeing vendors, including Contract Research Organizations (CROs), laboratory vendors, and other third parties, to ensure they meet timelines, budgets, quality, compliance, and goals.
  • Reaching patient recruitment goals by leading the operational strategy for identifying, recruiting, and retaining trial subjects.
  • Preparing clinical operations plans, timelines/costs/resources, documents/presentations for internal planning and study execution.
  • Leading efforts to identify and build relationships with key investigators and trial sites to ensure successful execution of clinical studies in compliance with GCP/ICH, global regulatory and patient safety requirements.
  • Supporting regulatory submissions including timeline planning, data preparation, document generation, inspection readiness, and query responses.
  • Representing the company as a senior clinical operations spokesperson before appropriate scientific, medical, regulatory, and business associates.

Tessera Therapeutics focuses on genetic medicine, specifically through a technology called Gene Writing, which enables precise modifications to the human genome. This technology allows for permanent changes to genetic material in any cell, aiming to cure diseases at their source. Tessera's Gene Writing can perform both small and large genetic alterations, making it applicable to a wide range of genetic disorders. The company collaborates with research institutions, pharmaceutical companies, and healthcare providers to develop new treatments. Tessera generates revenue through partnerships, licensing agreements, and the potential sale of its technology. With significant funding secured, Tessera's goal is to advance its Gene Writing platform to effectively rewrite genetic codes and address previously untreatable conditions.

Company Stage

Series C

Total Funding

$518.2M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

-8%

1 year growth

-10%

2 year growth

14%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tessera secured $300 million in Series C funding, boosting its platform development.
  • RNA Gene Writing technology shows promise in treating diseases like sickle cell and PKU.
  • The FDA's guidance on accelerated approval could expedite Tessera's Gene Writing treatments.

What critics are saying

  • Competing technologies like CRISPR may overshadow Tessera's Gene Writing advancements.
  • High development costs may hinder Tessera's market entry against larger competitors.
  • Ethical and regulatory challenges could delay Tessera's therapy approvals and adoption.

What makes Tessera Therapeutics unique

  • Tessera Therapeutics is pioneering Gene Writing, a novel approach in genetic medicine.
  • Gene Writing allows precise, permanent genetic alterations, surpassing traditional gene editing methods.
  • Tessera's technology targets a wide range of genetic disorders, offering versatile therapeutic solutions.

Help us improve and share your feedback! Did you find this helpful?